Last Updated: August 15, 2026

Litigation Details for iBeauty Limited Company v. Dbest Products Inc. (C.D. Cal. 2024)


✉ Email this page to a colleague

« Back to Dashboard


iBeauty Limited Company v. Dbest Products Inc. (C.D. Cal. 2024)

Docket 2:24-cv-10694 Date Filed 2024-12-12
Court District Court, C.D. California Date Terminated 2025-10-09
Cause 35:271 Patent Infringement Assigned To Michelle Williams Court
Jury Demand Plaintiff Referred To Jacqueline Chooljian
Patents 11,052,067
Link to Docket External link to docket
Small Molecule Drugs cited in iBeauty Limited Company v. Dbest Products Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

iBeauty Limited Company v. Dbest Products Inc. (2:24-cv-10694): Litigation Summary and IP Exposure Analysis

Last updated: July 28, 2026

What claims are at issue in iBeauty Limited Company v. Dbest Products Inc., 2:24-cv-10694?

The record provided does not include the complaint, causes of action, asserted intellectual property (e.g., patents, trademarks, copyrights, trade dress, or trade secrets), accused products, relevant dates, or the specific pleadings that define the case issues for iBeauty Limited Company versus Dbest Products Inc. in 2:24-cv-10694. With no access to those case-defining documents in the supplied material, a complete and accurate claims-level litigation summary cannot be produced.

What filings define the litigation posture?

A legally meaningful posture analysis requires the filings that typically drive early case understanding:

  • Complaint and exhibits (asserted rights, infringement bases, and product identification)
  • Answer and affirmative defenses
  • Motion to dismiss (Rule 12), if any
  • Motions for preliminary injunction or TRO, if any
  • Claim construction orders (if patents), Markman-related orders, if any
  • Scheduling order and discovery limits
  • Any amended complaint(s)
  • Dispositive orders and final judgments (if reached)

No such content is included in the input.

What IP categories are likely implicated?

The caption alone does not establish IP category. “iBeauty” and “Dbest Products” could involve consumer goods and branding, but the litigation outcome and risk profile depend on the specific right asserted (for example, trademark claims and likelihood-of-confusion factors differ from patent infringement elements and a Hatch-Waxman/IP carve-out timeline).

What has happened procedurally so far in the 2:24-cv-10694 case?

A procedural summary requires docket events (e.g., filing date, assigned judge, initial disclosures, service, scheduling, motion calendar, orders, settlement, or dismissal). The supplied information includes only the case caption and docket number. Without docket dates or orders, the procedural history cannot be accurately summarized.

How strong is the plaintiff’s position based on motion outcomes?

Strength analysis needs concrete indicators:

  • Denial or grant of motions to dismiss
  • Injunction issuance or denial
  • Rulings narrowing claims or defenses
  • Discovery rulings impacting evidence access
  • Summary judgment posture (if reached)

None of these indicators are present in the provided material.

Is there any settlement agreement or stipulation on record?

Settlement risk and exit pathways depend on whether:

  • The parties filed a stipulation of dismissal (with or without prejudice)
  • There is a consent judgment or licensing agreement
  • There is a settlement term sheet disclosure (rare in public dockets, but sometimes filed)

No such items are included in the input.

How do courts typically analyze the likely theory of liability in iBeauty v. Dbest?

A court’s liability framework depends on the asserted rights. With the specific causes of action missing, only category-level frameworks are possible, which would not meet a “complete and accurate response” standard.

If the case is trademark-related, what factors matter most?

Trademark infringement and related claims typically turn on:

  • Priority and validity of marks
  • Likelihood of confusion (Polaroid/Sleekcraft-like factors by circuit)
  • Fame strength, similarity of marks, evidence of actual confusion, channel-of-trade overlap, and intent

Without the complaint’s exact allegations and pleaded mark(s), this cannot be mapped to the case.

If the case is patent-related, what would the infringement analysis require?

Patent cases require:

  • Claim construction
  • Element-by-element infringement mapping
  • Doctrine of equivalents analysis (if applicable)
  • Validity arguments (anticipation, obviousness, indefiniteness, written description/enablement)
  • Potential venue and inequitable conduct defenses

None of the claim content or orders is provided.

If the case is trade dress or copyright-related, what is the key test?

These require different proof sets:

  • Trade dress: nonfunctionality and secondary meaning, plus confusion
  • Copyright: ownership and copying; substantial similarity analysis

No pleading facts are included in the input.

What is the litigation impact on product marketing, distribution, and enforcement risk?

Enforcement impact usually flows from:

  • Injunction scope (products, packaging, marketing channels)
  • Discovery targets (supplier information, design files, source codes, manufacturing)
  • Court-ordered labeling changes or cease-and-desist compliance

No injunction or order content is available in the prompt.

Which parties and counsel are involved, and how does that affect enforcement strategy?

A serious litigation strategy and risk assessment depends on:

  • Named counsel and their track records
  • Prior litigation history of the plaintiff or defendant
  • Whether the case is part of a broader enforcement program (common in trademark/consumer IP)
  • Prior registrations or patent families

The prompt does not include counsel names, jurisdictions, or prior enforcement patterns.

What damages and remedies are realistically in play in 2:24-cv-10694?

Remedies vary sharply by IP type:

  • Trademark: injunctive relief, profits, damages, attorneys’ fees (in some regimes)
  • Copyright: statutory damages, actual damages, attorneys’ fees
  • Patent: damages, enhanced damages, injunction in certain circumstances
  • Trade secrets: injunctive relief and misappropriation damages
  • Contractual claims: different frameworks

Because the asserted right(s) and demanded relief are not provided, a quantified or even directionally accurate remedies analysis cannot be produced.

Key Takeaways

  • The provided input contains only the case caption and docket number (iBeauty Limited Company v. Dbest Products Inc., 2:24-cv-10694) and does not include the complaint, docket events, or orders required for a complete and accurate litigation summary or legal analysis.
  • Without the pleaded claims, asserted IP rights, procedural history, and case-specific rulings, the litigation posture, risk profile, and likely outcome cannot be reliably determined.

FAQs

  1. What documents are required to summarize iBeauty Ltd. v. Dbest Products Inc. (2:24-cv-10694) accurately?
  2. How do you evaluate case strength without injunction or motion-to-dismiss rulings in the docket?
  3. What relief typically follows if the asserted right is trademark versus patent in federal court?
  4. How does the court’s scheduling order affect discovery scope and settlement leverage?
  5. What settlement signals show up in public dockets for IP cases like 2:24-cv-10694?

References

  1. None provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.